Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 12Stomach Neoplasms 4Colonic Neoplasms 2To Evaluate the Efficacy of Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Colorectal Carcinoma 1Rectal Neoplasms 1Platinum Resistant Ovarian Cancer 1Neoplasm Metastasis 1HER2-positive Colorectal Cancer 1HER2 IHC3+ Advanced Colorectal Cancer 1Esophageal Squamous Cell Carcinoma 1Endometrial Neoplasms 1Colorectal Cancer Metastatic 1Advanced Gastric Cancer 1

Interventions

sintilimab 1Tyrosine Kinase Inhibitors 1SHR-1701 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1Immune Checkpoint Inhibitors 1HMPL-013 1Decitabine 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Colorectal Cancer Metastatic × HMPL-013 × Clear all
NCT07621159 2026-06-02

A Phase Ib/II Study of HDM2017 in Combination With Standard of Care in Advanced Colorectal Cancer

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

Phase 1/2 Not yet recruiting
120 enrolled
Gastrointestinal

Colorectal Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡